Prognostic Value of IL-10 and Its Relationship with Disease Stage in Iranian Patients with Multiple Myeloma. Shekarriz R et al.Asian Pac J Cancer Prev. 2018 Jan 27;19(1):27-32. Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study. Wu C et al. Acad Radiol. 2018 Jan 16. pii: S1076-6332(17)30518-4. doi: 10.1016/j.acra.2017.12.008.…Details
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. Dhakal B et al. JAMA Oncol. 2018 Jan 4. doi: 10.1001/jamaoncol.2017.4600. [Epub ahead of print]. Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Gertz MA et al. Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012. Prolonged survival after second autologous transplantation and lenalidomide maintenance…Details
Hemostatic Abnormalities in Multiple Myeloma Patients. Gogia A et al. Asian Pac J Cancer Prev. 2018 Jan 27;19(1):127-130. Incidence of Second Primary Malignancies after Autologous Transplantion for Multiple Myeloma in the Era of Novel Agents. Sahebi F et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30021-1. doi: 10.1016/j.bbmt.2018.01.006. [Epub ahead of print]. Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem…Details
Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics. Kamande JW et al. Integr Biol (Camb). 2018 Jan 26. doi: 10.1039/c7ib00183e. [Epub ahead of print]. Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib…Details
The National Institute of Health and Care Excellence (NICE) has approved the use of daratumumab (Darzalex®) monotherapy as a treatment for relapsed and refractory myeloma patients. This treatment will be made available through the Cancer Drugs Fund (CDF) to patients in England and Wales who have received 3 prior treatments, including a proteasome inhibitor and…Details
Results from the Phase III TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial have recently been reported at the American Society of Haematology 2017 conference. This study assessed the benefit of levofloxacin antibiotic prophylaxis and its effect on healthcare associated infections in newly diagnosed myeloma patients. The results show that levofloxacin prophylaxis had a…Details
A meta-analysis conducted by researchers at the University of Pennsylvania has shown that treatment with carfilzomib (Kyprolis®) is associated with a higher incidence of cardiovascular events in myeloma patients. The study found that 18.1% of myeloma patients receiving carfilzomib experienced cardiovascular events, including hypertension, cardiac arrest, cardiac failure and arrhythmias, compared to only 3.8% of…Details
This document explains the aims of the Myeloma UK Nursing Best Practice Guides and how they should be used to enhance knowledge and inform nursing practice thus enabling nurses to deliver the highest possible treatment, care and support to myeloma patients and their families.
The purpose of this Guide is to enhance knowledge and inform nursing practice when providing psychological support to myeloma patients.
This Guide provides information and discusses best practice to support nurses caring for myeloma patients with oral mucositis.